VIRX News and Press, Viracta Therapeutics Inc. From 03/08/24

2024-03-08 08:51:48 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Viracta Therapeutics (NASDAQ: VIRX ) just reported results for the fourth quarter of 2023. Viracta Therapeutics reported earnings per share of -35 cents. This was below th...

2024-03-07 17:29:15 ET More on Viracta Therapeutics Seeking Alpha’s Quant Rating on Viracta Therapeutics Historical earnings data for Viracta Therapeutics Read the full article on Seeking Alpha For further details see: Viracta Therapeutics GAAP EPS...

Completed Stage 2 enrollment in the NAVAL-1 trial of Nana-val in patients with relapsed or refractory EBV + peripheral T-cell lymphoma supporting its speed to market strategy; topline results from Stage 1 of the study expected in the second quarter of 2024 Completed enrollme...

Accelerated pace of enrollment supports speed to market strategy Topline results from Stage 1 expected to be presented in the second quarter of 2024 followed by Stage 2 data in the third quarter of 2024 SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasda...

SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Execut...

Speed to market strategy for Nana-val in patients with relapsed or refractory EBV + peripheral T-cell lymphoma supported by complete enrollment of Stage 1, complete enrollment of Stage 2 anticipated in Q1 2024 and engagement with the FDA on potential accelerated approval pathway by mi...

2023-12-12 11:14:57 ET More on Viracta Therapeutics Viracta Therapeutics GAAP EPS of -$0.33 misses by $0.03 Seeking Alpha’s Quant Rating on Viracta Therapeutics Historical earnings data for Viracta Therapeutics Financial information for Viracta Therape...

First orphan drug designation for Nana-val granted in EBV + solid tumors Seventh orphan drug designation for Nana-val globally; fifth granted by the FDA SAN DIEGO, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision onc...

Confirmed partial responses without dose-limiting toxicities during dose escalation along with new preclinical data support the opportunity to further enhance efficacy through a novel split daily dosing regimen at higher dose levels of Nana-val Enrollment is underway for the sixth dose ...

2023-11-09 08:57:42 ET More on Viracta Therapeutics Seeking Alpha’s Quant Rating on Viracta Therapeutics Historical earnings data for Viracta Therapeutics Financial information for Viracta Therapeutics For further details see: Viracta Therapeutics ...